Relative Strength Rating
搜索文档
Exelixis Near A Buy Point. Relative Strength Rating Climbs.
Investors· 2025-12-18 19:19
TRENDING: The Next Big AI Concern Runs Through Main Street Today's Spotlight IBD's 12 Days of Holiday Deals Celebrate the holidays with big discounts on IBD's premium products every day from Dec. 13-24. Get Market Insights on IBD Live Join IBD Live to watch and discuss the market action in real time with a team of top market analysts. Is the Santa Claus Rally Real? Something big may be coming to town—check out IBD's guide to the Santa Claus Rally. More News Oracle Stock Jumps On Reports TikTok Signed Deal T ...
Catalyst Pharmaceuticals Stock Gets Relative Strength Rating Lift
Investors· 2025-12-15 19:59
Terms of Use Privacy Notice Accessibility About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Checkup Stock Quotes Stock Market Today The Big Picture My Stock Lists IBD Live Leaderboard SwingTrader MarketSurge IBD Digital MarketDiem The Wall Street Journal Barron's MarketWatch Dow Jones Smart Money Connect With Us On stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any speci ...
CarGurus Stock Sees Relative Strength Rating Drives Faster
Investors· 2025-12-15 19:49
Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or perfo ...
Aptiv Stock Sees Relative Strength Rating Lift
Investors· 2025-12-11 19:16
Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or perfo ...
Garry Ridge's Humility Drove His Leadership As WD-40 CEO
Investors· 2025-12-11 12:00
WD-40公司管理层与领导力发展 - 首席执行官Garry Ridge在1997年上任后进行了DISC人格测试 结果显示其具有主导型人格 倾向于以直接、果断、强势的风格行事 他意识到这可能会损害其领导力 并自嘲为“涡轮增压D型” [4] WD-40公司技术面表现 - WD-40的相对强度评级获得提升 显示出改善的技术表现 [4][5] - 公司正试图接近关键的技术指标基准 [7] - 尽管相对强度在上升 但仍未达到关键基准 [7] - 公司的IBD评级获得提升 显示出改进的技术实力 [7] 市场动态与投资主题 - 道琼斯指数微幅上涨 纳斯达克指数因投资者逃离科技股而暴跌 小盘股表现活跃 [7] - 有分析向客户推荐了10只预计将在2026年占据主导地位的股票 [6] - 埃隆·马斯克将特斯拉自动驾驶机器人出租车的倒计时设定为三周 [6] - 突破观察显示 拉夫·劳伦的竞争对手受到顶级基金的青睐 [6] - 盘前股票中有3只快速上涨 1只处于买入区域 [8]
Janux Therapeutics Craters 53% On Prostate Cancer Update; Is It An 'Overreaction'?
Investors· 2025-12-02 21:14
核心观点 - Janux Therapeutics (JANX) 更新了其前列腺癌药物JANX007的临床试验数据 导致股价在周二暴跌超过47% 但分析师认为市场反应过度 并对该药物的潜力和公司的前景保持乐观 [1][2][3] 临床试验数据更新 - 在可评估的27名去势抵抗性前列腺癌患者中 总体缓解率为30% 低于一年前更新中基于8名患者的50% [2] - 在89名接受两剂JANX007治疗的患者中 73%的患者达到PSA50(即前列腺特异性抗原水平下降50%) 26%的患者PSA水平下降90% [4] - 中位无进展生存期为7.3个月 在采用即将进入进一步测试的给药方案的患者亚组中 无进展生存期为7.9个月 [5] - 这些数据与安进和强生等竞争对手的药物基本一致 [5] 分析师观点与评级 - William Blair分析师Matt Phipps认为 关注那些采用即将进入Ib期研究的给药方案的患者组 以及在肿瘤负荷较低患者中的初步数据 表明JANX007有潜力成为同类最佳药物并实现重磅销售额 [3] - 该分析师维持对Janux股票的“跑赢大盘”评级 [8] - Wedbush分析师Robert Driscoll将Janux的目标股价从76美元大幅下调至45美元 但维持“跑赢大盘”评级 下调原因是基于对JANX007预期时间线的调整 [8] 安全性数据与方案优化 - 公司正在测试更新的治疗方案以改善细胞因子释放综合征的发生率 这是一种对某些癌症药物的危险炎症反应 [6] - 其中一种方案未导致严重细胞因子释放综合征病例 仅有一例轻微病例 [6] - 分析师指出 若能在持续研究中重现这种细胞因子释放综合征特征 将非常令人鼓舞 并可能使该疗法能够在门诊环境中使用 [7] 股价与市场表现 - 周二早盘交易中 Janux股价暴跌超过47% 至17.62美元 开盘价创下自2024年2月以来的最低点 [3] - 此次下跌使股价跌破了其50日和200日移动平均线 [9] - 在此次下跌前 公司股价从9月下旬的低点21.73美元上涨至本月晚些时候的高点35.34美元 涨幅近63% [9] - 其IBD数字相对强度评级已升至86(范围1-99) 该评级在三个月前为7 [9]
OneMain Holdings Stock Sees Relative Strength Rating Rise To 71
Investors· 2025-12-02 18:09
About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Checkup Stock Quotes Stock Market Today The Big Picture My Stock Lists Terms of Use Privacy Notice Accessibility About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Checkup Stock Quotes Stock Market Today The Big Picture My Stock Lists IBD Live Leaderboard SwingTrader MarketSurge IBD Digital MarketDiem The Wall Street Journal Barron's MarketWatch Dow Jones Smart Money Connect W ...
These Gold, Copper And Fintech Stocks Hit Relative Highs And Sit In Buy Zones
Investors· 2025-12-02 15:05
市场整体表现 - 纳斯达克指数领涨,股市开盘走高 [1] - 黄金和白银价格在周一上涨,提振部分矿业和黄金股 [1] 个股表现与筛选 - 沃尔玛股票在黑色星期五创下历史新高 [1][2] - Analog Devices公司与一家贵金属矿商股价亦创下新高 [1][2] - IBD股票筛选器识别出Enova International和Ero Copper等相对强弱线创新高的股票 [1] - Ero Copper上一季度利润跃升156%后获得关键评级上调 [4] 公司评级动态 - Enova International达到80以上相对强弱评级基准 [4] - Enova International的综合评级提升至96 [4] - Ero Copper的相对强弱评级改善至79 [4]
Marvell Technology Stock Sees RS Rating Jump To 86
Investors· 2025-12-01 19:06
市场整体表现 - 股市小幅收高,正趋向创纪录高点 [1][2] - 道琼斯期货上涨 [1] Marvell Technology 公司动态 - Marvell Technology 股票相对强度评级从75跃升至86,超过了80的关键基准 [1] - 公司股价因业绩超预期和与Celestial AI的交易而上涨 [1][4] - 公司相对强度评级获得提升,并接近关键的技术指标 [4] 其他个股表现 - American Eagle 股价因业绩报告而上涨 [1] - CrowdStrike 是盘后推动市场的业绩股之一 [1] - Rambus 作为AI数据中心概念股,股价飙升117%并测试关键水平 [4] 投资工具与评级 - IBD的独特评级通过1(最差)到99(最佳)的分数追踪市场领导地位 [1] - 关注相对强度评级80或更高是选股的一个重要指标 [1]
Urban Outfitters Stock Sees RS Rating Dresses Up For Holidays
Investors· 2025-11-28 18:59
Urban Outfitters 业绩与股价表现 - 公司股票相对强度评级从80跃升至85,超过了80的重要门槛 [1] - 股价在公布创纪录的第三季度业绩后飙升 [1] - 第三季度营收增长12%,达到15亿美元 [1] - 公司采用了多元化的战略 [1] 零售行业其他公司动态 - Burlington Stores在周二早些时候公布财报后,股价下跌超过12% [1][2] - 其他折扣零售商股价处于买入点之上 [1] - Ross Stores的相对强度评级达到87,显示出上升的市场领导力 [4] - Ross Stores在业绩超预期后股价上涨,折扣零售商正顺应某种购物趋势 [4] - Boot Barn Holdings的相对强度评级也达到了80以上的基准 [4] 整体市场与科技股情况 - 股市在经历大幅波动的一周后收涨 [1] - 道琼斯指数在震荡后上涨近500点 [4] - 英伟达股价在财报发布前波动,同时人工智能相关抛售加速 [4] - 一只道琼斯巨头股带领四只股票接近买入点 [4]